Novartis Pharmaceuticals Corporation
1 Health Plaza
East Hanover, NJ 07936
Telephone +1 888-669-6682

April 21, 2023

Dear Health Care Provider,

As an update to my previous communication to you regarding the supply of Pluvicto®, I would like to share that the FDA today approved our application to supply commercial doses of Pluvicto from our Radioligand Therapy (RLT) manufacturing facility in Millburn, New Jersey, for distribution in the US. Production will begin in the coming weeks and gradually ramp up. The site is expected to contribute meaningfully to supply in the third quarter after the anticipated approval of additional lines at the site. Capacity should continue to increase through the second-half of this year, helping to ensure stable, reliable supply to patients. The RLT manufacturing facility in Ivrea, Italy, will continue to supply the US market.

Our technical operations and customer service teams will be reaching out to you to help you understand how the gradual increase of supply will impact existing and new orders, as well as our expectations for scheduling into the second half of the year.

The approval of the Millburn facility is only a first step. We recognize the distress that our supply issues over the past months have caused you and your teams—and what this has meant to many patients and their loved ones. Please know that we will continue to do our best to deliver orders consistently while we scale up our RLT production capacity.

A new facility in Indianapolis, Indiana, is nearing completion, and is expected to open as soon as the end of this year, and capacity at the existing European facilities in Ivrea, Italy, and Zaragoza, Spain, is being expanded.

To support your own communication efforts, we are sharing two letters with you—for patients and referring physicians. We will also continue to provide updates on our RLT supply information site.

Please contact our team at 1-888-NOW-NOVA (1-888-669-6682) if you have any questions or feedback for us.

Sincerely,

Reshema Kemps-Polanco
Head, Novartis Oncology US